指南与共识心脑血管急症

《柳叶刀》冠状动脉疾病再思考委员会:从缺血转向动脉粥样硬化

The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma.
PubMed 文献 · Lancet · 2025-03-31
一句话结论委员会建议将冠状动脉疾病重新分类为动脉粥样硬化性冠状动脉疾病(ACAD),把重心从缺血和急性事件转向动脉粥样硬化的早期检出、预防与管理。

《柳叶刀》委员会指出,以心外膜冠状动脉阻塞导致心肌缺血为核心的传统范式存在缺陷:缺血出现时往往已错过最佳干预时机,治疗聚焦于阻塞后恢复血流这一临时方案,而非针对动脉粥样硬化本身。委员会建议将冠状动脉疾病重新分类为动脉粥样硬化性冠状动脉疾病(ACAD),在从胎儿期开始、贯穿儿童青少年至老年的全生命周期中识别和管理疾病各阶段。委员会提出预防须从早期检出和危险因素控制开始,若到2050年消除吸烟、高血压、高胆固醇和不良饮食等行为与代谢危险因素,ACAD死亡率可降低82.1%,每年或可挽救870万生命。委员会还指出高收入国家与低中收入国家在预防、诊断和治疗上存在差异,2022至2050年中低偏下收入国家ACAD死亡率预测上升19.2%、中高偏上收入国家上升4.2%。

要点

  • 委员会建议把冠状动脉疾病重新分类为动脉粥样硬化性冠状动脉疾病(ACAD),重心从缺血和急性事件转向动脉粥样硬化全程。
  • 委员会提出若到2050年消除吸烟、高血压、高胆固醇和不良饮食等危险因素,ACAD死亡率可降低82.1%,每年或可挽救870万生命。
  • 委员会认为应以早期检出、预防和管理动脉粥样硬化替代以急性事件为中心的诊疗策略,在疾病最早阶段即识别ACAD。
  • 委员会预测2022至2050年ACAD死亡率在中低偏下收入国家上升19.2%、中高偏上收入国家上升4.2%,强调预防、诊断和治疗的公平可及。
  • 委员会提出卫生系统应优先投入预防和早期检出,并相应调整医务人员教育培训与研究资助方向。

适用人群与场景

  • 委员会讨论对象为冠状动脉疾病人群,强调ACAD风险终身存在:始于宫内,经儿童和青少年期进展,持续至老年。
  • 委员会关注高收入国家与低中收入国家在预防、诊断和治疗上的差异及由此导致的健康结局差异。

处置流程与药物剂量

  • 委员会提出预防ACAD必须从早期检出和改变危险因素开始,包括吸烟、高血压、高胆固醇和不良饮食等行为与代谢危险因素。
  • 委员会提出应将针对高危个体的筛查策略整合进卫生保健系统,以检出动脉粥样硬化早期征象并及时干预。
  • 委员会提出卫生保健系统应设计为优先进行ACAD的预防和早期检出,而不是仅仅治疗晚期疾病。
  • 委员会提出ACAD治疗需要综合的国际性方案,包括增加研究资助、开发新疗法和投资早期检出方法。

研究设计与关键结果

  • 本文件为《柳叶刀》委员会报告,指出传统以心外膜冠状动脉阻塞和心肌缺血为核心的范式存在缺陷:缺血显现时往往已错过最佳干预,治疗聚焦于阻塞后恢复血流的临时方案而非针对基础疾病。
  • 委员会指出心肌梗死的主要机制为动脉粥样硬化斑块破裂或糜烂,程度较轻的钙化结节破出可在疾病更早期阶段出现,而现有诊疗主要集中于症状识别和急性事件处理。
  • 委员会预测若到2050年消除吸烟、高血压、高胆固醇和不良饮食等危险因素,ACAD死亡率可降低82.1%,每年或可挽救870万生命。
  • 委员会预测2022至2050年间ACAD死亡率在中低偏下收入国家上升19.2%、中高偏上收入国家上升4.2%。

证据类型、等级与局限

  • 证据类型:学会/委员会报告(《柳叶刀》委员会)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 委员会建议将冠状动脉疾病重新分类为动脉粥样硬化性冠状动脉疾病(ACAD),把重点从缺血和急性心脏事件转向对动脉粥样硬化的系统性理解,以便在病程更早期识别和管理疾病。
  • 委员会提出目标不应仅是管理症状和事件,而是从一开始就预防疾病发生,并在可能时逆转其进程。
  • 委员会提出需从根本上转变医务人员的教育和培训,聚焦疾病早期阶段并将预防策略整合进临床实践。
  • 委员会提出当前研究不足、与疾病全球负担不匹配,且研究未代表多样人群,常忽视低中收入国家的特定需求。

指南或共识出处

  • 《柳叶刀》冠状动脉疾病再思考委员会(The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma),《柳叶刀》(The Lancet)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Coronary artery disease has long been understood through the paradigm of epicardial coronary artery obstruction, causing myocardial ischaemia (a mismatch between myocardial blood supply and demand). However, this model, which focuses on diagnosing and managing coronary artery disease based on ischaemia and cardiovascular events, is flawed. By the time ischaemia manifests, it is often too late for optimal intervention, limiting the effectiveness of treatment options. Despite decades of medical advances, coronary artery disease continues to be a leading cause of morbidity and mortality globally, highlighting the inadequacy of this traditional ischaemic-centric approach. The central limitation of current approaches is the focus on the temporary solutions of restoring myocardial blood flow after obstruction, rather than tackling the underlying disease. Coronary artery disease, caused by atherosclerosis, often results in myocardial infarction through mechanisms that emerge earlier in the progression of disease. The focus of medical care has predominantly been on the recognition of symptoms and treatment of acute events, missing opportunities for early detection and prevention of disease. Billions of dollars in health-care funding continue to be spent on identifying and managing coronary ischaemia; yet, the dominant mechanisms for myocardial infarction are atherosclerotic plaque rupture or erosion and, to a lesser extent, erupted calcified nodules that can emerge at a much earlier stage of the disease. This Commission advocates for a shift in the conceptual framework of coronary artery disease. We suggest reclassifying the condition as atherosclerotic coronary artery disease (ACAD), moving away from the traditional emphasis on ischaemia and acute cardiac events towards a more systematic understanding of atherosclerosis. This reframing will enable the identification and management of the disease much earlier in its course, potentially saving millions of lives worldwide. Risk of ACAD develops over a lifetime, beginning in utero, progressing through childhood and adolescence, and continuing into older age. The early stages of disease, which involve the formation of atherosclerotic plaques, are often undetected. A major shift is needed from acute event-centred care to strategies focused on early diagnosis, prevention, and management of atherosclerosis. In this new framework, ACAD should be recognised across all stages, from the earliest signs of atheroma formation to the advanced stages of disease. Our goals should not just to be to manage symptoms and events but to prevent the disease from developing in the first place and, where possible, reverse its course.

EARLY DETECTION AND PREVENTION OF ACAD: The prevention of ACAD must begin with early detection and modification of risk factors. If behavioural and metabolic risk factors, such as smoking, hypertension, high cholesterol, and poor diet, were eliminated or controlled early in life, the global burden of ACAD could be dramatically reduced. Eliminating these risk factors by 2050 could decrease the rate of ACAD deaths by 82·1%, potentially saving 8·7 million lives annually. Public health initiatives should emphasise lifestyle changes and the management of metabolic disorders to prevent the onset of atherosclerosis. Early detection and effective prevention remain a challenge. The implementation of screening strategies to identify individuals at risk of developing ACAD is crucial. Targeted screening programmes, integrated into health-care systems, can detect early signs of atherosclerosis and enable timely intervention. Such interventions, if applied early, have the potential to halt, delay, or even reverse the progress of the disease, reducing the risk of cardiovascular events in later life.

ADDRESSING THE GLOBAL BURDEN OF ACAD: ACAD is not a uniform problem across the globe. Disparities exist between high-income countries and low-income to middle-income countries in terms of prevention, diagnosis, and treatment. These differences contribute to variations in health outcomes. Between 2022 and 2050, mortality rates from ACAD are forecasted to increase by 19·2% in lower-middle-income countries and 4·2% in upper-middle-income countries. This global disparity underscores the importance of equitable access to prevention, diagnosis, and treatment to reduce the global burden of ACAD. Health-care systems must be designed to prioritise prevention and early detection of ACAD rather than simply treating advanced disease. This prioritisation requires a fundamental shift in the education and training of health-care providers, with a focus on the early stages of the disease and the integration of prevention strategies into clinical practice. A comprehensive international approach to ACAD treatment requires increased research funding, the development of novel treatments, and investment in early detection methods. The development of new therapies to prevent, reverse, and eradicate atherosclerosis is crucial. Research funding must be increased to support these efforts, particularly in the development of transformative therapies and imaging technologies that can accurately assess disease progression at all stages. Current research is insufficient and does not match the global burden of the disease. Research is not representative of diverse populations, often neglecting the specific needs of low-income and middle-income countries. More research is needed to ensure that clinical pathways for the prevention and treatment of ACAD are adaptable and effective across all health-care settings. The reframing of coronary artery disease as ACAD represents a crucial shift in the way we approach the disease. By recognising ACAD as a lifelong condition, from early atherosclerotic plaques to advanced disease, and shifting priority towards early detection, prevention, and treatment, the potential to save millions of lives annually is substantial. Implementing these changes will require global collaboration, increased investment, and a commitment to equitable health-care delivery. Stakeholders should work together towards the stabilisation, reversal, and ultimate elimination of ACAD, reducing the global burden of this preventable disease.

The Lancet Group takes a neutral position with respect to territorial claims in any published maps and institutional affiliations.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Zaman S, Wasfy JH, Kapil V, et al. The Lancet Commission on rethinking coronary artery disease: moving from ischaemia to atheroma. Lancet. 2025. PMID: 40179933. doi:10.1016/S0140-6736(25)00055-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。